- Home
- WATT vs SNOA Comparison
WATT vs SNOA Comparison
Compare WATT & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WATT
- SNOA
- Stock Information
- Founded
- WATT 2012
- SNOA 1999
- Country
- WATT United States
- SNOA United States
- Employees
- WATT N/A
- SNOA N/A
- Industry
- WATT Radio And Television Broadcasting And Communications Equipment
- SNOA Biotechnology: Pharmaceutical Preparations
- Sector
- WATT Technology
- SNOA Health Care
- Exchange
- WATT Nasdaq
- SNOA Nasdaq
- Market Cap
- WATT 3.9M
- SNOA 3.7M
- IPO Year
- WATT 2014
- SNOA 2007
- Fundamental
- Price
- WATT $0.30
- SNOA $2.74
- Analyst Decision
- WATT Strong Buy
- SNOA
- Analyst Count
- WATT 2
- SNOA 0
- Target Price
- WATT $2.25
- SNOA N/A
- AVG Volume (30 Days)
- WATT 350.0K
- SNOA 316.6K
- Earning Date
- WATT 11-12-2024
- SNOA 02-06-2025
- Dividend Yield
- WATT N/A
- SNOA N/A
- EPS Growth
- WATT N/A
- SNOA N/A
- EPS
- WATT N/A
- SNOA N/A
- Revenue
- WATT $431,184.00
- SNOA $13,547,000.00
- Revenue This Year
- WATT $95.75
- SNOA $23.89
- Revenue Next Year
- WATT $834.07
- SNOA $25.45
- P/E Ratio
- WATT N/A
- SNOA N/A
- Revenue Growth
- WATT N/A
- SNOA 11.81
- 52 Week Low
- WATT $0.28
- SNOA $2.44
- 52 Week High
- WATT $2.75
- SNOA $9.40
- Technical
- Relative Strength Index (RSI)
- WATT 21.40
- SNOA 44.93
- Support Level
- WATT $0.28
- SNOA $2.44
- Resistance Level
- WATT $0.34
- SNOA $3.25
- Average True Range (ATR)
- WATT 0.04
- SNOA 0.21
- MACD
- WATT -0.00
- SNOA -0.02
- Stochastic Oscillator
- WATT 7.55
- SNOA 23.46
About WATT Energous Corporation
Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. Its products include Transmitter IC & Module, Receivers IC, Transmitter System and other tools.
About SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.